Aptevo Therapeutics Inc. (APVO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aptevo Therapeutics Inc. on April 29, 2025. The filing reports on an "Other Event" (Item 8.01) regarding the amendment of an existing At The Market (ATM) Offering Agreement with Roth Capital Partners, LLC.
Key Financial Metrics
The filing details a specific equity offering under the Sales Agreement dated April 28, 2025:
- Aggregate Offering Price: Up to $3,167,548.
- Shares Issued and Sold (as of filing date): 305,845 shares of Common Stock.
- Aggregate Gross Sale Proceeds: $181,848.
- Price per Share: $0.5946.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics beyond the proceeds from this specific offering.
Material Changes
The primary material change is the filing of a Prospectus Supplement to amend and supplement the prior prospectus filed on April 28, 2025. This action updates the offering parameters under the Company's effective Form S-3 registration statement (File No. 333-284969).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It includes standard legal disclaimers stating that the report does not constitute an offer to sell or a solicitation of an offer to buy the shares in jurisdictions where such offers would be unlawful. The offering is subject to the terms of the Prospectus and the Sales Agreement.
Investor Verification Checklist
- Verify the total number of shares sold under the ATM program since April 28, 2025, to assess dilution impact.
- Confirm the current cash balance and burn rate to determine how long the $181,848 in proceeds will extend the company's runway.
- Review the full Prospectus Supplement and the underlying Form S-3 for use of proceeds details.
- Check for any subsequent filings regarding additional share sales under the $3.17 million cap.